TORONTO, June 9, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on June 10, 2021 at 10:00 AM EDT (7:00 AM PDT). HLS welcomes stakeholders, investors, and other individual followers to register and attend this live event.

The event will feature Gilbert Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer. The Company's presentation will be followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the Company's Investor website.

REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-tsx-hls-2021-06-10-100000   

To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

Copyright 2021 Canada NewsWire

HLS Therapeutics (TSX:HLS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more HLS Therapeutics Charts.
HLS Therapeutics (TSX:HLS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more HLS Therapeutics Charts.